VBI Vaccines Claws Back With New Data [Seeking Alpha]
VBI Vaccines, Inc. - Ordinary Shares (VBIV)
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
vbivaccines.com/investors
Company Research
Source: Seeking Alpha
Summary VBI Vaccines collapsed back in June because HBV candidate Sci-B-Vac failed to achieve noninferiority after 2 doses to SOC Engerix B after 3 doses for all age groups. New data from a second phase III trial show that Sci-B-Vac has achieved noninferiority after 2 doses to Engerix B after 3 in the 18-44 subgroup. Really, this new data is not surprising, because the initial Phase III data already suggested this was highly likely to be the case. VBI may have risen back up for other reasons as well, including safety over Heplisav B, cost, and possible future recommendation as a 2-course vaccine by ACIP for the 18-44 subgroup. Well, VBI Vaccines ( VBIV DVAX In my previous coverage of these events, which I recommend reviewing regained compliance VBI put it this way in its press release: As per the commonly-used statistical margin of non-inferiority for vaccines1, defined as the lower limit of the 95% CI being above -10%, this analysis demonstrated non-inferiority after two doses of Sci
Show less
Read more
Impact Snapshot
Event Time:
VBIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VBIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VBIV alerts
High impacting VBI Vaccines, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
VBIV
News
- VBI Vaccines Inc. (NASDAQ: VBIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- VBI Vaccines Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Reports Full Year 2023 Financial ResultsBusiness Wire
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBusiness Wire
VBIV
Earnings
- 11/14/23 - Miss
VBIV
Sec Filings
- 4/17/24 - Form SC
- 4/16/24 - Form 10-K
- 4/16/24 - Form 8-K
- VBIV's page on the SEC website